Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study

Annals of Oncology : Official Journal of the European Society for Medical Oncology
G SperaJohn Mackey

Abstract

Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in patients with a range of cancers. Although limited and discordant data suggest that BB may increase overall survival (OS) in localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC. To explore the association between BB use and BC outcomes, we retrospectively reviewed ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo. We compared progression-free survival (PFS), OS, overall response rate, and clinical benefit rate in patients who received BB to those who did not. 153/1144 (13%) patients received BB; 62% prior to enrolment and 38% began after enrolment. Median PFS in BB treated patients was longer than in patients who did not receive them (10.3 versus 8.3 months; HR 0.81; 95% CI 0.66-0.99; P = 0.038). Patients treated with BB only after enrolment had even higher median PFS (15.5 versus 8.3 months, P < 0.001). In the TNBC subset, median PFS was 13.0 months with BB, compared to 5.2 months without BB (HR 0.52; 95% CI 0.34-0.79; P = ...Continue Reading

References

Aug 9, 2003·Cancer Chemotherapy and Pharmacology·Masami NiiyaMitsune Tanimoto
Jan 30, 2007·Endocrine-related Cancer·E Tiligada
Sep 9, 2010·Cancer Research·Erica K SloanSteven W Cole
Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amal Melhem-BertrandtAna-Maria Gonzalez-Angulo
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas I BarronKala Visvanathan
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John R MackeyRodrigo Fresco
Mar 5, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R MackeyUNKNOWN Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators
Apr 17, 2016·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Lars Ivo ParteckeWolfram von Bernstorff
May 18, 2016·Cancer Treatment Reviews·Janick WeberpalsHermann Brenner

❮ Previous
Next ❯

Citations

May 18, 2018·Epidemiology·Gonzalo SperaJohn R Mackey
Mar 22, 2019·The Cancer Journal·Stefania OrecchioniFrancesco Bertolini
Sep 19, 2019·Oncogene·Shu-Heng JiangZhi-Gang Zhang
Sep 26, 2020·Frontiers in Oncology·Shirui DaiZhaoyang Zeng
Sep 28, 2020·Cancer Chemotherapy and Pharmacology·Heitor Pinhata CecilioDaniel Galera Bernabé
Oct 18, 2019·Cancer Prevention Research·Boris MravecPavel Babal
Feb 7, 2021·Bone Research·Francisco ConceiçãoMeriem Lamghari
Jul 12, 2020·Journal of Neuroimmunology·Boris MravecLubica Horvathova
Jul 3, 2021·International Journal of Molecular Sciences·Boris Mravec

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

© 2022 Meta ULC. All rights reserved